Coleman RL, Fleming GF, Brady MF, et al. - In this international, phase 3, placebo-controlled trial, individuals were randomized to receive chemotherapy plus placebo followed by placebo maintenance (control), chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only), or chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout) in order to evaluate the effectiveness of veliparib added to first-line induction chemotherapy with carboplatin and paclitaxel and continued as maintenance monotherapy in individuals with formerly untreated stage III or IV high-grade serous ovarian carcinoma. A total of 1,140 people underwent randomization in 1:1:1 ratio. It was discovered that in all trial populations, compared with carboplatin plus paclitaxel induction therapy alone, a regimen of carboplatin, paclitaxel, and veliparib induction therapy followed by veliparib maintenance therapy resulted in significantly longer PFS. However, the independent value of adding veliparib during induction therapy without veliparib maintenance was insufficiently clear.